 Sarepta Therapeutics Inc which is seeking US regulatory approval for a drug to treat a rare childhood disease recently moved to limit Chief Executive Chris Garabedians broad sway over operations especially his role in discussions with the Food and Drug Administration The step was taken in response to the concerns of some company executives who worried Mr Garabedians involvement in the regulatory discussions was counterproductive according to people familiar with the matter 